1255936-24-3

Basic information

• Product Name: S)-2-((Methoxycarbonyl)aMino)-3-Methylbutanoic acid
• Synonyms: 4-(4-bromophenyl)-2-[(2S)-2-pyrrolidinyl]-1H-imidazole;(S)-4-(4-bromophenyl)-2-(pyrrolidin-2-yl)-1H-imidazole(WXG03505)
• CAS NO: 1255936-24-3
• Molecular Formula: C₁₃H₁₄BrN₃
• Molecular Weight: 292.19
• EINECS: -0
• Mol File: 1255936-24-3.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• CAS DataBase Reference: S)-2-((Methoxycarbonyl)aMino)-3-Methylbutanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: S)-2-((Methoxycarbonyl)aMino)-3-Methylbutanoic acid(1255936-24-3)
• EPA Substance Registry System: S)-2-((Methoxycarbonyl)aMino)-3-Methylbutanoic acid(1255936-24-3)

Safety Data

• Hazardous Substances Data: 1255936-24-3(Hazardous Substances Data)

Upstream product

• 1007881-98-2 y 
• 99-73-0 para-bromophenacyl bromide 
• 7644-04-4 4-bromophenacylamine 
• 1007882-04-3 (S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]pyrrolidine-1-carboxylic acid tert-butyl ester 
• 128120-93-4 (S)-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromophenyl)-2-oxoethyl]ester 1-tert-butyl ester 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 147-85-3 L-proline 
• 59936-29-7 (S)-N-(tert-butoxycarbonyl)proline methyl ester 
• 1007882-04-3 (S)-tert-butyl 2-(5-(4-bromophenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 

Downstream Products

• 1255936-26-5 C₂₃H₂₃BrN₄O₃ 
• 1228552-27-9 ((S)-1-{(S)-2-[5-(4-bromophenyl)-1H-imidazol-2-yl]pyrrolidine-1-carbonyl}-2-methylpropyl)carbamic acid methyl ester 
• 1228553-33-0 [(S)-2-methyl-1-((S)-2-{5-[4-(4,4,5,5 tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester 
• 1228553-01-2 [(S)-1-((S)-2-{4-[2-(4-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-3H-imidazol-4-yl}-phenyl)-quinolin-6-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester 
• 1261072-22-3 methyl {(2S)-1-[(2S)-2-{5-[4-(2-chloroquinolin-6-yl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 
• 1261072-42-7 methyl {(2S)-1-[(2S)-2-{5-[4-(6-bromo-4-cyanoquinolin-2-yl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 
• 1261072-48-3 methyl {(2S)-1-[(2S)-2-{4-[4-(7-hydroxyquinolin-3-yl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 
• 1228553-35-2 methyl {(2S)-3-methyl-1-oxo-1-[(2S)-2-{5-[4-(2-{2-[(2S)-pyrrolidin-2-yl]-1H-imidazol-5-yl}quinolin-6-yl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-yl]butan-2-yl}carbamate 
• 1228553-37-4 methyl {(2S)-1-[(2S)-2-{5-[4-(2-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methyl-butanoyl}pyrrolidin-2-yl]-1H-imidazol-4-yl}quinolin-6-yl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 
• 1261071-70-8 methyl {(2S)-1-[(2S)-2-{5-[4-(4-cyano-6-{2-[(2S)-pyrrolidin-2-yl]-1H-imidazol-5-yl}quinolin-2-yl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 
• 1261070-45-4 methyl {(2S)-1-[(2S)-2-{5-[4-(4-cyano-6-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-4-yl}quinolin-2-yl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 
• 1228633-22-4 methyl {(2S)-3-methyl-1-oxo-1-[(2S)-2-{5-[4-(6-{2-[(2S)-pyrrolidin-2-yl]-1H-imidazol-5-yl}naphthalen-2-yl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-yl]butan-2-yl}carbamate 
• 1261070-48-7 methyl {(2S)-1-[(2S)-2-{5-[4-(6-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]butanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}naphthalen-2-yl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 
• 1373164-81-8 C₁₉H₂₆BrN₃O₂Si 

Relevant articles and documents

Monoglycosyl-containing heterocyclic compound for inhibiting hepatitis C viruses and preparation method

The invention discloses a monoglycosyl-containing heterocyclic compound for inhibiting hepatitis C viruses and a preparation method. The monoglycosyl-containing heterocyclic compound has a chemical structure represented by a formula I shown in the description. The monoglycosyl-containing heterocyclic compound disclosed by the invention can be used for effectively inhibiting protease of the hepatitis C viruses and treating infection of the hepatitis C viruses (HCV).

Synthesis and evaluation of novel HCV replication inhibitors

Abstract: Direct acting antiviral agents to cure hepatitis C virus (HCV) infection has emerged as the gold standard therapy. Along with protease inhibitors, nucleoside polymerase inhibitors and non-nucleoside polymerase inhibitors, the inhibition of NS5a

SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS

Disclosed are spiro compounds of formula (I), or stereomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof. The compounds can be used to treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore disclosed are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions in the treatment of HCV infection or hepatitis C disease.